-
Editorial Team
Posts
Gilead halts emergency access to COVID-19 contender remdesivir amid ‘overwhelming demand’
Since the early days of the current coronavirus outbreak, Gilead Sciences’ experimental antiviral drug remdesivir has been hailed as a leading hope. That halo has...
UPDATED: Biogen staffer fled to China in search of emergency Covid-19 testing, care — and now faces criminal charges
A Biogen employee who has contracted Covid-19 in Massachusetts fled to Beijing alongside her family. And now she faces criminal charges for lying about her condition...
Alzheimer’s Disease: New Therapeutic Digest eBook
Currently, there are 5.1 million people with Alzheimer’s disease in the United States and 13 million worldwide. In 30 years, AD is expected to affect...
These are the most disruptive companies shaking up healthcare, executives say
Healthcare executives are keeping their eyes on Amazon. And given the tech giant’s expanding reach in healthcare, that’s not too surprising. But when KLAS Research asked more...
Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study
Osaka, Japan, and Chicago October 22, 2019 –Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”) today announced that Takeda has...
Biotech GSK gives Clover adjuvant for vaccine against ‘indispensable’ COVID-19 protein
GlaxoSmithKline has struck a deal to provide its pandemic adjuvant to Clover Biopharmaceuticals for use in a COVID-19 vaccine candidate. Clover is one of a clutch of...
The clinical trials initiated in the United States and in Israel will evaluate safety, tolerability and efficacy of PrimeC, NeuroSense’s product for ALS patients.
HERZLIYA, Israel, Feb. 6, 2020 /PRNewswire/ — NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow or halt ALS progression, announced today the initiation...
11 drugs likely to become blockbusters
The 11 drugs Clarivate expects to become blockbusters by 2024: Rimegepant (Biohaven Pharmaceutical) — designed to treat migraines. OMG-157 (Novartis) — designed to treat multiple...
Collaboration Formed to Develop New Radiochemicals for Diagnosing, Treating Brain Diseases
A collaborative effort between Fuzionaire Diagnostics, McGill University and The Neuro (Montreal Neurological Institute-Hospital) will foster the development of a new class of radioactive molecules — called radiochemicals — for...
Major cancer institute sued by its own researchers over ‘tapering’ funding
Alleging that a leading cancer funder is slashing their support in an “unethical and reckless” way, six prominent cancer researchers at the University of California,...